Nuvalent EBIT

Nuvalent (NUVL) currently reports a EBIT of $-460M as of March 2026. That compares with $-320M in the prior-year period — down 41.1% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Nuvalent's EBIT history and peer comparisons.

Nuvalent's EBIT decreased from $-320M to $-460M — a 41.1% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Nuvalent's EBIT of $-460M is lower than the Healthcare sector average of $23B. That is roughly 102.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Nuvalent reported $-460M in EBIT as of March 2026. That compares with $-320M in the prior-year period — down 41.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-460M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Nuvalent, and consider following NUVL for alerts when major investors trade the stock.